PL356423A1 - Nowa krystaliczna postać kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo[2,3-d]-pirymidyn-5-ylo)-etylo]-benzoilo]-L-glutaminowego i proces jej przygotowania - Google Patents

Nowa krystaliczna postać kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo[2,3-d]-pirymidyn-5-ylo)-etylo]-benzoilo]-L-glutaminowego i proces jej przygotowania

Info

Publication number
PL356423A1
PL356423A1 PL01356423A PL35642301A PL356423A1 PL 356423 A1 PL356423 A1 PL 356423A1 PL 01356423 A PL01356423 A PL 01356423A PL 35642301 A PL35642301 A PL 35642301A PL 356423 A1 PL356423 A1 PL 356423A1
Authority
PL
Poland
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
PL01356423A
Other languages
English (en)
Other versions
PL208061B1 (pl
Inventor
Erik Christopher Chelius
Susan Marie Reutzel-Edens
Den Berghe Snorek Sharon Van
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL356423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL356423A1 publication Critical patent/PL356423A1/pl
Publication of PL208061B1 publication Critical patent/PL208061B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PL356423A 2000-02-25 2001-02-12 Postać krystaliczna heptahydratu soli disodowej kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo [2,3-d]-pirymidyn-5-ylo) etylo] benzoilo]-L-glutaminowego i jej zastosowanie PL208061B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (en) 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (2)

Publication Number Publication Date
PL356423A1 true PL356423A1 (pl) 2004-06-28
PL208061B1 PL208061B1 (pl) 2011-03-31

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356423A PL208061B1 (pl) 2000-02-25 2001-02-12 Postać krystaliczna heptahydratu soli disodowej kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo [2,3-d]-pirymidyn-5-ylo) etylo] benzoilo]-L-glutaminowego i jej zastosowanie

Country Status (35)

Country Link
US (1) US7138521B2 (pl)
EP (1) EP1259513B1 (pl)
JP (1) JP4846158B2 (pl)
KR (1) KR100744917B1 (pl)
CN (1) CN1183135C (pl)
AR (1) AR029471A1 (pl)
AT (1) ATE249462T1 (pl)
AU (1) AU777047B2 (pl)
BR (1) BR0108604A (pl)
CA (1) CA2400155C (pl)
CO (1) CO5261585A1 (pl)
CZ (1) CZ303772B6 (pl)
DE (1) DE60100750T2 (pl)
DK (1) DK1259513T3 (pl)
DZ (1) DZ3283A1 (pl)
EA (1) EA004684B1 (pl)
EG (1) EG24073A (pl)
ES (1) ES2206403T3 (pl)
HR (1) HRP20020701B1 (pl)
HU (1) HU229704B1 (pl)
IL (2) IL150480A0 (pl)
MX (1) MXPA02008242A (pl)
MY (1) MY124784A (pl)
NO (1) NO323422B1 (pl)
NZ (1) NZ519796A (pl)
PE (1) PE20011082A1 (pl)
PL (1) PL208061B1 (pl)
PT (1) PT1259513E (pl)
SI (1) SI1259513T1 (pl)
SK (1) SK287375B6 (pl)
SV (1) SV2002000321A (pl)
TW (1) TWI237024B (pl)
UA (1) UA72791C2 (pl)
WO (1) WO2001062760A2 (pl)
ZA (1) ZA200205265B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
KR101083230B1 (ko) 2006-08-14 2011-11-11 시코르, 인크. 페메트렉세드 이산의 동결 건조된 약학적 허용염의 제조 방법
US7994180B2 (en) * 2006-08-14 2011-08-09 Sicor Inc. Processes for preparing intermediates of pemetrexed
JP2008543975A (ja) 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
EP2270012A1 (en) * 2006-08-14 2011-01-05 Sicor, Inc. Crystalline form of pemetrexed diacid and process for the preparation thereof
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
BRPI0807939A2 (pt) 2007-04-03 2014-07-01 Reddys Lab Ltd Dr Formas sólidas de pemetrexed
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
WO2010028105A2 (en) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Amorphous pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
EP2504341A1 (en) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG A new crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
EP2688888B1 (en) 2011-03-25 2017-06-14 Scinopharm Taiwan, Ltd. Process for the production of disodium pemetrexed
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
US20150359898A1 (en) 2013-02-06 2015-12-17 Cipla Limited Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes
US20160051679A1 (en) 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
US20160145260A1 (en) 2013-06-14 2016-05-26 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
EP3021849B1 (en) 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
DK3040074T3 (en) 2013-10-03 2018-10-08 Fujifilm Corp INJECTION PREPARATION AND METHOD OF PREPARING IT
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA3015436C (en) 2014-10-30 2020-07-21 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
ES2959975T3 (es) * 2017-10-10 2024-02-29 Sun Pharmaceutical Ind Ltd Forma de dosificación para infusión intravenosa de pemetrexed
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
WO1998008382A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
WO1999016742A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Processes and intermediates useful to make antifolates
AU6890800A (en) * 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
WO2001062760A2 (en) 2001-08-30
DK1259513T3 (da) 2004-01-12
NO20023974L (no) 2002-08-21
SK287375B6 (sk) 2010-08-09
DZ3283A1 (fr) 2001-08-30
PE20011082A1 (es) 2001-10-22
HRP20020701A2 (en) 2003-12-31
SV2002000321A (es) 2002-07-16
ZA200205265B (en) 2003-11-11
DE60100750T2 (de) 2004-07-29
HUP0204232A3 (en) 2006-01-30
HRP20020701B1 (en) 2011-02-28
KR20020075449A (ko) 2002-10-04
CN1183135C (zh) 2005-01-05
AR029471A1 (es) 2003-07-02
EG24073A (en) 2008-05-11
HU229704B1 (en) 2014-05-28
CZ20022875A3 (cs) 2003-02-12
SI1259513T1 (en) 2003-12-31
US7138521B2 (en) 2006-11-21
US20030216416A1 (en) 2003-11-20
ES2206403T3 (es) 2004-05-16
HUP0204232A2 (hu) 2003-04-28
AU777047B2 (en) 2004-09-30
PL208061B1 (pl) 2011-03-31
WO2001062760A3 (en) 2001-12-06
JP2003530321A (ja) 2003-10-14
BR0108604A (pt) 2002-11-19
KR100744917B1 (ko) 2007-08-01
CN1406238A (zh) 2003-03-26
AU3445101A (en) 2001-09-03
ATE249462T1 (de) 2003-09-15
CZ303772B6 (cs) 2013-05-02
EP1259513B1 (en) 2003-09-10
HK1051856A1 (en) 2003-08-22
JP4846158B2 (ja) 2011-12-28
UA72791C2 (uk) 2005-04-15
EP1259513A2 (en) 2002-11-27
DE60100750D1 (de) 2003-10-16
IL150480A0 (en) 2002-12-01
CA2400155C (en) 2009-09-15
PT1259513E (pt) 2004-02-27
NO20023974D0 (no) 2002-08-21
NZ519796A (en) 2003-01-31
CA2400155A1 (en) 2001-08-30
CO5261585A1 (es) 2003-03-31
EA004684B1 (ru) 2004-06-24
SK11862002A3 (sk) 2003-01-09
MY124784A (en) 2006-07-31
EA200200905A1 (ru) 2003-02-27
NO323422B1 (no) 2007-04-30
TWI237024B (en) 2005-08-01
MXPA02008242A (es) 2002-11-29
IL150480A (en) 2007-12-03

Similar Documents

Publication Publication Date Title
PL356423A1 (pl) Nowa krystaliczna postać kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo[2,3-d]-pirymidyn-5-ylo)-etylo]-benzoilo]-L-glutaminowego i proces jej przygotowania
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
PL373679A1 (pl) Sposoby otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
IL202582A0 (en) New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
NO2014030I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
EP1945645A1 (en) Crystalline forms of pemetrexed diacid and processes for the preparation thereof
CA2031890A1 (en) N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
AU7288100A (en) Regulation of secondary metabolite production
PL370406A1 (pl) Krystaliczne hydraty pochodnych anilidu kwasu nikotynowego i anilidu kwasu benzoesowego
HUP0402253A3 (en) Process for the purification of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethylacetamide(zaleplon) and the preparation of its novel crystalline forms and pharmaceutical compositions containing the latters
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
WO2001017959A3 (en) Vitronectin receptor antagonists
PL357106A1 (pl) Nowy sposób wytwarzania -(2,4-disulfofenylo)-N-tert-butylonitronu i jego farmaceutycznie dopuszczalnych soli
AU2001291233A1 (en) Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
IL157061A (en) Process and intermediates for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl)piperazin -1-yl)-methanone and salts thereof
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AU2001296746A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
AU2002213119A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
PL337788A1 (en) Method of obtaining 1-{[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazole[3,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl}-4-methylpiperazine
AU5297296A (en) Piperidine derivatives as diuretic
SI1265856T1 (en) Novel process for the preparation of alpha-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
AU2002230022A1 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof
AU2002302635A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof
AU2002255007A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof